Maxim raised the firm’s price target on Augmedix to $5 from $4 and keeps a Buy rating on the shares. Augmedix’s Q4 results highlight its attractive business model of monthly recurring revenue under annual contracts, a multi-billion total addressable market, expanded offerings with Notes, an iOS adaptable solution, coding and pre-charting, and wallet share growth with existing customers, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AUGX:
- Augmedix reports Q4 revenue $8.751M, consensus $8.51M.
- Augmedix Reports Strong Commercial Traction and Sales Momentum; Reports Fourth Quarter and Full Year 2022 Financial Results
- Augmedix Inc (AUGX) Q4 Earnings Cheat Sheet
- Augmedix to Announce Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on March 27, 2023
- Augmedix Announces Participation in Oppenheimer’s 33rd Annual Healthcare Conference